Company name:
Enanta Pharmaceuticals Inc
-
IPO SHARE PRICE:$14.00
-
IPO DATE:March 21, 2013
-
TICKER:ENTA
-
MAIN STOCK EXCHANGE:NASDAQ
-
CURRENT HQ LOCATION:500 Arsenal Street Watertown Massachusetts 02472
-
FISCAL YEAR END:September 30
-
INCORPORATION JURISDICTION:DE
-
ORGANIZED AS THE FOLLOWING LEGAL TYPE:Corporation
-
Investor Relations Webpage:Coming soon!
-
TAX RATE:USA federal corporate nominal income tax rate is 21%
Short Description
Enanta Pharmaceuticals Inc
We are working hard and as soon as possible to provide company description soon. Feel free to reach out to request it sooner: improve@real-clear-investing.com
Statement of Cash Flow
(USD in thousand)
Selected Year:
30-Sep
2020
2020
OPERATING ACTIVITIES
Cash received and spent on operating activites of business — buying materials, paying salaries, receiving payments from clients, etc
42.7% -
Accounts receivable
30.1% -
Stock-based compensation
16.3% -
Deferred income taxes
5.6% -
Depreciation and amortization
4.9% -
Operating lease right-of-use assets
0.5% -
(Accretion) amortization of (discount) premium on marketable securities
SOURCEs
42.7%
4.9%
5.6%
16.3%
30.1%
100 %
0%
USES
10.9%
5.4%
17.5%
5.5%
55.5%
55.5% -
Net income (loss)
17.5% -
Prepaid expenses and other assets
5.5% -
Premium paid on marketable securities
5.4% -
Operating lease liabilities
2.1% -
Accrued expenses
1.4% -
Other liabilities
1.4% -
Accounts payable
0.2% -
Change in fair value of warrant liability and Series 1 non-convertible preferred stock
0.1% -
Other non-cash items
|
|
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (loss) | $71,956 | $46,383 | ($36,168) | ($57,939) | ($33,312) | |||||||
Depreciation and amortization
|
2,518 | 3,258 | 3,644 | 3,611 | 3,484 | |||||||
Stock-based compensation
|
15,845 | 19,226 | 19,575 | 19,360 | 19,532 | |||||||
(Accretion) amortization of (discount) premium on marketable securities
(Accretion) amortization of (discount) premium on marketable securities
|
(835) | (4,336) | 304 | 1,065 | 1,724 | |||||||
Non-cash interest expense
|
- | - | - | - | - | |||||||
Excess tax benefit related to stock-options compensation
Excess tax benefit related to stock-options compensation
|
- | - | - | - | - | |||||||
Income tax benefit from stock awards
|
- | - | - | - | - | |||||||
Deferred income taxes
|
1,858 | (3,138) | 10,608 | 9,951 | - | |||||||
(Gain) loss on sale of property and equipment
|
- | - | - | - | - | |||||||
Gain or loss on sale of marketable securities
|
- | - | - | - | - | |||||||
(Gain) loss on derivative
|
- | - | - | - | - | |||||||
Change in fair value of warrant liability
|
- | - | - | - | - | |||||||
Change in fair value of warrant liability and Series 1 non-convertible preferred stock
Change in fair value of warrant liability and Series 1 non-convertible preferred stock
|
59 | - | (149) | (149) | - | |||||||
Premium paid on marketable securities
|
(319) | (1,491) | (3,575) | (3,612) | (4,100) | |||||||
Other non-cash items
|
(75) | 25 | (51) | (51) | - | |||||||
Unbilled receivables
|
- | - | - | - | - | |||||||
Accounts receivable
|
(56,591) | 15,892 | 27,821 | 20,827 | (33,004) | |||||||
Operating lease right-of-use assets
|
- | - | 3,184 | 3,816 | 4,608 | |||||||
Prepaid expenses and other assets
|
(918) | (10,845) | (11,397) | (13,850) | (5,228) | |||||||
Other assets
|
(92) | - | - | - | - | |||||||
Accounts payable
|
1,317 | 1,791 | (883) | (129) | 2,300 | |||||||
Income tax payable
|
(7,910) | (1,388) | - | - | - | |||||||
Accrued expenses
|
1,843 | 5,750 | (1,368) | 2,123 | (9,992) | |||||||
Deferred revenue
|
- | - | - | - | - | |||||||
Operating lease liabilities
|
- | - | (3,535) | (4,231) | (5,156) | |||||||
Other liabilities
|
564 | 291 | (922) | (959) | (416) | |||||||
Net cash provided by (used in) operating activities | $29,220 | $71,418 | $7,088 | ($20,165) | ($59,560) |
Selected Year:
30-Sep
2020
2020
INVESTING ACTIVITIES
Cash spent on acquiring plant, equipment and other businesses, cash recei0 from sale of plant, equipment and subsidiaries as well cash parked temporarily in different securities - government bonds typically
100.0% -
Maturities and sales of marketable securities
SOURCEs
100.0%
100 %
0%
USES
5.5%
94.1%
94.1% -
Purchases of marketable securities
0.4% -
(Purchase) sale of property and equipment
|
|
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
(Increase) decrease in restricted cash and deposits
|
- | - | - | - | - | |||||||
Purchases of marketable securities
|
(293,103) | (549,312) | (338,553) | (325,766) | (418,696) | |||||||
Sale of marketable securities
|
- | - | - | - | - | |||||||
Maturities of marketable securities
|
- | - | - | - | - | |||||||
Maturities and sales of marketable securities
|
260,682 | 468,065 | 359,828 | 366,497 | 349,668 | |||||||
(Purchase) sale of property and equipment
|
(2,981) | (5,417) | (1,445) | (1,145) | (752) | |||||||
Other investing activities
|
- | - | - | - | - | |||||||
Net cash provided by (used in) investing activities | ($35,402) | ($86,664) | $19,830 | $39,586 | ($69,780) |
Selected Year:
30-Sep
2020
2020
FINANCING ACTIVITIES
Items in this group are concerned with borrowing funds, repaying debt, issuing equity, buying back shares, etc.
100.0% -
Proceeds from issuance of common stock upon exercise of stock options and warrants
SOURCEs
100.0%
100 %
0%
USES
85.7%
14.3%
14.3% -
Payments for settlement of share-based awards
|
|
|
|
|
|
|
|
|
|
|
|
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
Initial Public Offering (IPO) net
|
- | - | - | - | - | |||||||
Proceeds from issuance of common stock upon exercise of stock options
Proceeds from issuance of common stock upon exercise of stock options
|
- | - | - | 14,964 | - | |||||||
Proceeds from issuance of common stock upon exercise of stock options and warrants
Proceeds from issuance of common stock upon exercise of stock options and warrants
|
6,244 | 6,848 | 10,481 | 10,481 | - | |||||||
Payments for settlement of share-based awards
|
(1,756) | (4,188) | (1,498) | (892) | (2,136) | |||||||
Initial public offering costs
|
- | - | - | - | - | |||||||
Issuance of Convertible Notes
|
- | - | - | - | - | |||||||
Repayment of convertible notes
|
- | - | - | - | - | |||||||
Repayments of capital leases
|
(79) | (86) | - | - | - | |||||||
Payments of withholding tax on equity-based compensation
Payments of withholding tax on equity-based compensation
|
- | - | - | - | - | |||||||
Income tax benefit from exercise of stock options
|
- | - | - | - | - | |||||||
Net cash provided by (used in) financing activities | $4,409 | $2,574 | $8,983 | $8,116 | $1,196 |
Selected Year:
30-Sep
2020
2020
NET CHANGE IN CASH
Grand Total for sum of cash flows coming from operations, investing and financing
$35,901,000